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Volume-assured pressure support mode plus pirfenidone as 
resuscitation therapy in patients with exacerbation of idiopathic 
pulmonary fibrosis
Abstract 
Introduction: Treatment among advanced stage idiopathic pulmonary fibrosis is quite challenging, especially considering that no 
major evidence has been released about it. This case report demonstrates and discusses the benefit of non-invasive mechanical 
ventilation in volume-assured pressure support (AVAPS) mode plus pirfenidone based on the relief of a patient’s symptoms in 
combination with high-resolution computed tomography (HRCT) evidence.
Material and methods: An 83-year-old female patient with multiple hospital admissions within a  six-month period initially 
presented with cardiac symptoms which were later attributed to a possible exacerbation of her primary diagnosis, idiopathic 
pulmonary fibrosis.
Conclusion: The addition of non-invasive mechanical ventilation in AVAPS mode plus pirfenidone can improve the survival rates 
even in patients with current exacerbations of acute respiratory failure due to idiopathic pulmonary fibrosis.
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Introduction 
Idiopathic pulmonary fibrosis (IPF) is the 
most frequent and devastating form of idiopathic 
interstitial pneumonias. The average survival 
time from diagnosis is 3 years. It commonly 
affects people older than 60. IPF is a  chronic 
fibrotic interstitial lung disease (ILD) characte-
rized by progressive loss of lung function with 
symptoms including dyspnea and cough [1]. The 
American Thoracic Society, European Respiratory 
Society, Japanese Respiratory Society, and Latin 
American Thoracic Association guidelines indi-
cate that a diagnosis of IPF should be based on: 
a) Exclusion of other known causes of interstitial 
lung disease (e.g., domestic and occupational 
environmental exposures, connective tissue dise-
ase, and drug toxicity); b) Presence of a usual inter-
stitial pneumonia (UIP) pattern on high-resolution 
CT (HRCT) in patients who have not undergone 
surgical lung biopsy; and c) Specific combinations 
of HRCT and surgical lung biopsy pathological 
patterns in patients who have undergone surgical 
lung biopsy [2]. The American Thoracic Society 
defines exacerbation as: a) Previous or concurrent 
diagnosis of IPF; b) Acute worsening, or develop-
ment of dyspnea typically < 1-month duration; 
c) Computed tomography with new bilateral 
ground-glass opacity and/or consolidation su-
perimposed on a background pattern consistent 
with a  usual interstitial pneumonia pattern; 
d) Deterioration not fully explained by cardiac fa-
ilure or fluid overload [3]. Patients with IPF frequ-
ently suffer from acute exacerbations, which could 
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be due to single or multiple factors [4]. Pirfenidone 
was recently found to be effective for a patient with 
an acute exacerbation of IPF (AE-IPF) [5]. 
Based on high in-hospital mortality rates, 
current treatment guidelines state that many 
patients with respiratory failure due to AE-IPF 
should not receive mechanical ventilation, ma-
inly because of the aforementioned high morta-
lity rates. There are no studies suggesting that 
mechanical ventilation (including non-invasive 
ventilation) might be successful [6–8]. Furthermo-
re, the use of non-invasive mechanical ventilation 
in these patients has been questioned due to the 
possibility of futility [9]. 
We present this case to show that the com-
bination of noninvasive mechanical ventilation 
in AVAPS mode plus pirfenidone might provide 
a different perspective towards the clinical appro-
ach of ventilatory management for these patients.
Material and methods 
An 83-year-old female patient who was 
transferred from another hospital presented to 
the emergency department with a 4-week histo-
ry of productive cough, low production of white 
expectoration, and marked dyspnea (class III 
MRC (Medical Research Council) dyspnea scale). 
The patient was diagnosed with AE-IPF based 
on the American Thoracic Society guidelines: 
a) Worsening dyspnea; b) New findings on HRCT, 
and c) Significantly decreased PaO2. According to 
the criteria, these findings should occur within 
1 month of one another without any other cau-
sative factor (e.g. infection); c) During admis-
sion, the patient was conscious and dyspnea 
was clearly observed. There was no evidence of 
cardiac symptoms or possible cardiac involve-
ment and no manifestation of hemodynamic 
compromise. 
IPF had been diagnosed in a  tertiary refer-
ral hospital approximately 1-year prior to the 
admission to our hospital. The diagnosis of IPF 
included a transbronchial biopsy that exhibited 
characteristic pathological patterns. 
Physical examination showed rhythmic heart 
sounds, hypoventilated lung fields with the presence 
of bilateral basal crepitations, and a Glasgow score 
of 15/15. Laboratory tests indicated normal blood 
count (Leukocytes — 7.87 mm3), normal inflamma-
tory markers (Monocytes — 14.7%, Lymphocytes — 
15.1%, Neutrophils — 64.6%, Eosinophils — 3.99%), 
Hematocrit — 32.6%, Hemoglobin — 10.8 g/dL, Red 
Blood Cells — 373 mm3, Platelets — 429 mm3, 
ALT — 35 U/L, AST — 41 U/L, LDH — 246 U/L) 
and serum creatinine was 0.7 mg/dL.
The HRCT revealed diffuse bilateral pleuro-
pulmonary infiltrations accompanied by areas of 
fibrosis in the lung bases (Figure 1).
The patient remained under hospital supervi-
sion for four days with clinical suspicion of an 
AE-IPF exacerbation and was discharged after 
observed improvement.
One week later, the patient returned to the emer-
gency department complaining of cough without 
expectoration, as well as use of accessory muscles 
of breathing (especially sternocleidomastoids). 
White blood cell count, prior to admission, 
was as follows: Leukocytes — 9.93 mm3; Neutro-
phils — 66.8%. CRP value was: 2.0 mg/L.
Figure 1. High-resolution computed tomography of the chest on initial presentation. Peripheral ground-glass, traction bronchiectasis. Reticulated 
opacities were distributed throughout the basal lungs; honeycombing was absent
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Blood and sputum cultures, along with mo-
lecular investigations for atypical respiratory 
pathogens remained negative.
After assessment in the emergency depart-
ment, the patient was admitted to the intensive 
care unit (ICU). The patient was started on treat-
ment consisting of sodium chloride for hydration, 
ampicillin-sulbactam, salbutamol, fluticasone, 
salmeterol, enoxaparin, furosemide, and hydro-
cortisone 400 mg/day.
The initial arterial blood gas analysis showed: 
pH — 7.47, PaCO2 — 33.6 (mm Hg), PaO2 — 45.2 
(mm Hg), HCO3 —24 (mmoL/ L), excess base — 
1.9, and SO2 — 85%.
The Echocardiogram reports showed eviden-
ce of preserved global and segmental contractility 
with an ejection fraction (EF) of 72.8% and an 
estimated systolic pulmonary artery pressure 
(PSAP) of 32 mm Hg.
Ventilatory parameters 
The ventilatory parameters were initially 
programmed in the BiPAP S/T-AVAPS (volume-
-assured pressure support) (AVAPS) Tidal volume 
programmed AVAPS (ml) 400 mL, levels of IPAP 
programmed maximum — 14 (cmH2O). 
Levels of IPAP patient — 14 (cmH2O), levels of 
EPAP — 8 (cmH2O), RAMP — 3 (msec), inspiratory 
time — 1.2 (sec), tidal volume patient — 398 (mL), 
Vmin — 18 (L/min), leak — 10 (cmH2O), FiO2 — 70 (%). 
During the fifth day in the ICU, treatment 
with pirfenidone was administered at 200 mg 
orally three times daily (600 mg/day). This tre-
atment was based on the IPF diagnosis and was 
initiated after obtaining informed consent from 
the patient and her surrogates. 
The patient was then transferred at which 
point she and her relatives decided to establish 
a “do not resuscitate order”. Through advanced 
care planning, cardiopulmonary resuscitation 
(CPR) and/or invasive mechanical ventilation 
would not be attempted. However, clinical mana-
gement was sustained. During the hospitalization, 
she continued with NIV for 9 days (approximately 
20 hours a day) with a high percentage of inspired 
(FiO2) 70%, and with the use of a rebreather mask 
during the rest periods of NIV in AVAPS mode.
The patient presented slight erythema on the 
nasal bridge due to skin irritation from the facial 
mask. On day 10, we decided to increase the dose of 
pirfenidone to 1200 mg/day. On day 12, the patient 
began to decrease daily use of NIV in AVAPS mode to 
18 hours/day, requiring less percentage inspired FiO2 
(65%). On day 16, the dose of pirfenidone was incre-
ased to 2400 mg/day and the patient presented with 
ruddiness of the face along with a sensation of heat as 
a result of the use of pirfenidone. On day 19, NIV was 
decreased to 10 hours a day with FiO2 50%. On day 
24, the use of NIV in AVAPS mode was decreased to 
3 hours, twice daily. On day 26 of hospitalization, the 
patient began to wear a facial oxygen mask at 5 L/min. 
After 27 days of hospitalization, the patient was 
finally discharged with an oxygen mask, receiving 
pirfenidone at the dose of 1200 mg/d. 
Follow-up
The patient had consultations throughout the 
year after her initial presentation in the hospital, 
and the evaluation showed a marked decrease 
in patchy opacities. Figure 3 shows a marked 
decrease in ground-glass opacities at 18 months 
after treatment with pirfenidone. Forced and slow 
spirometry manouvers are shown in Figure 4.
Minute ventilation (VE), peak oxygen con-
sumption (VO2), and carbon dioxide released 
(VCO2) measured breath by breath (Software 
PistonXP version 1.61 PRE-201 Ergospirome-
ter) (Piston Ltd.’s respiratory diagnostics), and 
12-lead ECG (BTL CardioPoint-Ergo E600). Data 
was continuously recorded. After 3 min of resting 
Figure 2. CT notes a notable decrease in opacities in upper lung segments in the axial section
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Figure 3. CT note the decrease in opacities in upper lung lobes in the coronal section 18 months after treatment with pirfenidone
Figure 4. Forced spirometry and slow spirometry maneuvers in which the flow-volume curve shows an ascending branch of rapid rise in expiratory loop 
with a restrictive pattern and a reduction in inspiratory capacity
and 2 min of warm up, the exercise load was in-
creased every 3 min by 25 watts; as determined 
for patients with interstitial disease and chronic 
pulmonary disease. She pedaled at about 50 to 
60 revolutions per min. The following data was ob-
tained: VO2 9.18 ml/kg/min (51% predictor), VCO2 
9.41 ml/kg/min, respiratory exchange ratio (RER) 
1.15, Load 50 watts, breaths rate (BR) 47 breat/min, 
VE 28 (38%), coefficient minute ventilation/VO2 
production (VE/VO2) 46.7;  coefficient minute 
ventilation/VCO2 production (VE/VCO2) 82,5, 
coefficient VO2 production/heart rate (VO2/HR) 
8,4 mL/b,  coefficient VO2 production/work 
rate (WR) 4,70 mL/min/watts,  HR maximum 
157 heart/min; maximum (Figure 5).
Discussion
IPF is defined as a specific form of chronic, 
progressive, fibrosing interstitial pneumonia of 
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supplemental oxygen, and broad-spectrum an-
tibiotics. International treatment guidelines 
include a weak recommendation for the use of 
high-dose corticosteroids in the management of 
patients with AE-IPF, based on very low-quality 
evidence. 
In the case of our patient, she received noni-
nvasive mechanical ventilation (NIV) plus pirfe-
nidone, the latter therapy beginning on the fifth 
day of hospitalization. These resulted in clinical 
improvement with a gradual decrease in oxygen 
requirement (inspired FiO2) and time of use of NIV. 
Hence, current IPF guidelines state that while the 
majority of patients with respiratory failure due 
to IPF should not receive mechanical ventilation, 
it may be a reasonable intervention in a minority 
of patients (weak recommendation, low-quality 
evidence) and that NIV may be appropriate in 
some patients [11].
Management of AE-IPF in the ICU may be 
justified, particularly in patients in whom the pos-
sibility of lung transplantation exists and in those 
who have not yet undergone clinical evaluation 
for the cause of their respiratory decline [12].
Patients with IPF often present common 
comorbidities such as pulmonary hypertension 
[13], obstructive sleep apnea, lung cancer, chronic 
obstructive pulmonary disease (COPD) / emphy-
sema, ischemic heart disease, and GERD [14], 
which demand holistic approach in the disease 
management.
Conclusion 
In our case, we facilitated the recovery of 
a patient with AE-IPF who had marked hypoxemia 
and ventilatory work, normal blood chemistry and 
adequate renal function. The patient remained on 
NIV in AVAPS mode to avoid intubation. Pirfeni-
done was added at high doses that were achieved 
progressively and which were well tolerated. 
The patient experienced progressive clinical 
improvement with declining oxygen requirements 
and NIV time until her hospital discharge at 
which time she no longer required NIV. Follow-
-up after one year demonstrated that the patient 
maintained a reduced lung function with minimal 
oxygen requirements at home, and her chest CT 
showed a notable improvement in opacities in 
upper lung segments in the axial section.
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Figure 5. VE/VCO2 value during incremental cardiopulmonary exercise 
testing VE/VCO2 (coefficient minute ventilation/VCO2 production)
unknown cause. IPF shows the usual interstitial 
pneumonia (UIP) pattern, pathologically and/ 
/or radiologically. Recently, an official ATS, ERS, 
JRS, and LATA consensus statement (the current 
IPF guideline) advocated that the presence of 
characteristic UIP findings (“UIP pattern”) on 
thin-section CT images is sufficient for diagnosing 
IPF/UIP without pathologic evaluation by surgical 
lung biopsy in appropriate clinical settings [1]. 
Pirfenidone inhibits transforming growth factor-b 
(TGF-b) and has antifibrotic, anti-inflammatory, 
and antioxidant effects. Pirfenidone is the first 
antifibrotic agent that has been approved by the 
FDA for the treatment of IPF and has recently 
been found to be effective for a patient with 
AE-IPF [10]. 
AE-IPF is defined as any respiratory event 
characterized by new bilateral ground-glass 
opacification/consolidation not fully explained 
by cardiac failure or fluid overload, which pa-
rallels the Berlin Criteria for acute respiratory 
distress syndrome. However, there is difficulty in 
distinguishing idiopathic from respiratory events 
triggered by known causes (apart from cases with 
evident infectious pneumonia); both idiopathic 
and triggered events (e.g. infection, post-proce-
dural/postoperative, drug toxicity, aspiration) 
resulting in worsening respiratory symptoms and 
widespread alveolar damage can be diagnosed as 
AE-IPF. The difference between AE triggered by 
infection and pneumonia in terms of therapeutic 
strategy and prognosis remains unknown. 
No treatments have been shown to be effec-
tive in the manegement of acute exacerbations. 
Patients usually require hospital admission, 
Advances in Respiratory Medicine 2020, vol. 88, no. 1, pages 147–152
152 www.journals.viamedica.pl
References:
1. Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel 
concepts of proton pump inhibitors as antifibrotic drugs. Am J 
Respir Crit Care Med. 2016; 193(12): 1345–1352, doi: 10.1164/
rccm.201512-2316PP, indexed in Pubmed: 27110898.
2. Raghu G, Rochwerg B, Zhang Y, et al. American Thoracic Socie-
ty; European Respiratory society; Japanese Respiratory Society; 
Latin American Thoracic Association. An Official ATS/ERS/
JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic 
pulmonary fibrosis. An update of the 2011 clinical practice 
guideline. Am J Respir Crit Care Med. 2015; 192(2): 13–19.
3. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of 
idiopathic pulmonary fibrosis. An international working group 
report. Am J Respir Crit Care Med. 2016; 194(3): 265–275, doi: 
10.1164/rccm.201604-0801CI, indexed in Pubmed: 27299520.
4. Song JW, Hong SB, Lim CM, et al. Acute exacerbation 
of idiopathic pulmonary fibrosis: incidence, risk fac-
tors and outcome. Eur Respir J. 2011; 37(2): 356–363, doi: 
10.1183/09031936.00159709, indexed in Pubmed: 20595144.
5. Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and 
efficacy of pirfenidone in severe idiopathic pulmonary fibro-
sis: A real-world observational study. Pulm Pharmacol Ther. 
2017; 46: 48–53, doi: 10.1016/j.pupt.2017.08.011, indexed in 
Pubmed: 28843616.
6. Gaudry S, Vincent F, Rabbat A, et al. Invasive mechanical 
ventilation in patients with fibrosing interstitial pneumonia. 
J Thorac Cardiovasc Surg. 2014; 147(1): 47–53, doi: 10.1016/j.
jtcvs.2013.06.039, indexed in Pubmed: 23968871.
7. Rush B, Wiskar K, Berger L, et al. The use of mechanical ven-
tilation in patients with idiopathic pulmonary fibrosis in the 
United States: A nationwide retrospective cohort analysis. Re-
spir Med. 2016; 111: 72–76, doi: 10.1016/j.rmed.2015.12.005, 
indexed in Pubmed: 26733227.
8. Vianello A, Arcaro G, Battistella L, et al. Noninvasive ven-
tilation in the event of acute respiratory failure in patients 
with idiopathic pulmonary fibrosis. J Crit Care. 2014; 29(4): 
562–567, doi: 10.1016/j.jcrc.2014.03.019, indexed in Pubmed: 
24768565.
9. Briones Claudett KH. Noninvasive ventilation in the event of 
acute respiratory failure in patients with idiopathic pulmo-
nary fibrosis: waiting for? J Crit Care. 2014; 29(6): 1128, doi: 
10.1016/j.jcrc.2014.07.016, indexed in Pubmed: 25201432.
10. Ohkubo H, Kunii E, Moriyama S, et al. Efficacy of combined 
corticosteroid and pirfenidone for acute exacerbation of idio-
pathic pulmonary fibrosis after surgery for lung cancer: a case 
report. Respir Investig. 2015; 53(1): 45–47, doi: 10.1016/j.resi-
nv.2014.09.003, indexed in Pubmed: 25542603.
11. Mallick S. Outcome of patients with idiopathic pulmonary fi-
brosis (IPF) ventilated in intensive care unit. Respir Med. 2008; 
102(10): 1355–1359, doi: 10.1016/j.rmed.2008.06.003, indexed 
in Pubmed: 18635345.
12. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive venti-
lation in acute exacerbation of idiopathic pulmonary fibrosis. 
Internal Medicine. 2010; 49(15): 1509–1514, doi: 10.2169/in-
ternalmedicine.49.3222.
13. Castria D, Refini RM, Bargagli E, et al. Pulmonary hyperten-
sion in idiopathic pulmonary fibrosis: prevalence and clinical 
progress. Int J Immunopathol Pharmacol. 2012; 25(3): 681–
689, doi: 10.1177/039463201202500314, indexed in Pubmed: 
23058018.
14. Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic 
pulmonary fibrosis patients: a systematic literature review. Eur 
Respir J. 2015; 46(4): 1113–1130, doi: 10.1183/13993003.02316-
2014, indexed in Pubmed: 26424523.
